Ranbaxy Receives Tentative Approval for Zidovudine Tablets As Part of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Initiative
Posted on: Thursday, 14 July 2005, 12:01 CDT
PRINCETON, N.J., July 14 /PRNewswire/ -- Ranbaxy Laboratories Limited (RLL) announced today that it has received tentative approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Zidovudine Tablets USP, 300 mg. This is the first approval granted by the USFDA for generic Zidovudine. This is also Ranbaxy's third tentative approval from the USFDA under the latter's expedited review process under the US President's Emergency Plan for AIDS Relief (PEPFAR). Zidovudine Tablets are indicated for use in combination with other antiretroviral (ARV) agents in the treatment of HIV infection.
Ranbaxy's Zidovudine Tablets are manufactured at the company's state-of- the-art manufacturing facilities that have also been approved by the USFDA. The Contract Research Organizations (CROs) used by Ranbaxy to carry out bio- equivalence studies for its ARVs are audited by, and file their studies routinely with, some of the most stringent regulatory authorities around the world.
Commenting on this development, Dr. Brian W. Tempest, CEO and Managing Director, RLL, said, "We are committed to making quality ARVs available to HIV/AIDS patients throughout the world. We are pleased with the speed with which USFDA has moved in approving our products and will continue to work with them for the approval of our remaining ARVs in support of PEPFAR. Simultaneously, we are extending full cooperation to WHO, so that they can also approve the same products under their pre-qualification program."
Generic ARVs are essential to winning the worldwide struggle against HIV/AIDS, an epidemic now infecting approximately 40 million people around the globe. More than 20 million individuals have so far succumbed to this devastating disease.
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances with ground operations in 44 countries and manufacturing operations in 7 countries.
Ranbaxy Laboratories Limited
CONTACT: Charles M. Caprariello, Vice President, CorporateCommunications, Ranbaxy Inc., +1-609-720-5615; Edwige Buteau, +1-212-994-7517,or Anuj Baveja, +1-212-994-7552, both of RF Binder Partners Inc. for RanbaxyLaboratories Limited
Web site: http://www.ranbaxy.com/
Source: PRNewswire
Related Articles
- Video: Wayne Newton's Limited Engagement Production Once Before I Go Celebrates Grand Opening at Tropicana Las Vegas
- Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
- Ranbaxy Given Final Approval for Simvastatin
- FDA Approves Schering-Plough's Anti-Fungal Drug
- Inhaled-Insulin Sales Approved BRs Pennington Center Tested Drug, Alternate to Injections
- Biotechnology Firms Race for FDA Approval on Rival Growth-Stimulating Drugs
- Ranbaxy Gains Tentative Approval to Market Additional Strengths of Glimepiride Tablets
- Czech Government Approves Action Plan Against Illegal Drug
- Ranbaxy Receives Final Approval for Clarithromycin XL 1000 Mg Tablet
 |
 |
User Comments (0)
RSS Feeds